CanSino Biologics Inc., (HKG: 6185), a leading vaccine specialist based in China, has entered into a strategic partnership with Asymchem Laboratories (Tianjin) Co., Ltd (SHE: 002821), a Contract Development and Manufacturing Organization (CDMO). This collaboration is designed to drive the development of cutting-edge technologies that align with market demands. The partnership will concentrate on innovation in the development of biopharmaceutical macromolecules, encompassing plasmids, mRNA drugs, and LNP (lipid nanoparticle) delivery systems. The financial specifics of the agreement have not been disclosed.
The alliance between CanSino Biologics and Asymchem Laboratories is expected to leverage their respective expertise to advance the biopharmaceutical industry, focusing on the research and manufacturing of innovative drug delivery platforms. This partnership underscores the commitment of both companies to push the boundaries of biopharmaceutical innovation and to meet the evolving needs of the global healthcare market.- Flcube.com
